A detailed history of Globeflex Capital L P transactions in Catalyst Pharmaceuticals, Inc. stock. As of the latest transaction made, Globeflex Capital L P holds 46,398 shares of CPRX stock, worth $1 Million. This represents 0.09% of its overall portfolio holdings.

Number of Shares
46,398
Previous 228,784 79.72%
Holding current value
$1 Million
Previous $3.54 Million 73.98%
% of portfolio
0.09%
Previous 0.37%

Shares

11 transactions
Quarter Operation Price Per share shares change shares Held SEC Form
Q3 2024

Nov 13, 2024

SELL
$15.19 - $21.35 $2.77 Million - $3.89 Million
-182,386 Reduced 79.72%
46,398 $922,000
Q4 2023

Feb 13, 2024

SELL
$11.78 - $17.29 $64,790 - $95,095
-5,500 Reduced 2.35%
228,784 $3.85 Million
Q3 2023

Nov 13, 2023

SELL
$11.69 - $15.02 $727,258 - $934,424
-62,212 Reduced 20.98%
234,284 $2.74 Million
Q2 2023

Aug 14, 2023

SELL
$11.5 - $18.08 $88,492 - $139,125
-7,695 Reduced 2.53%
296,496 $3.98 Million
Q1 2023

May 12, 2023

SELL
$14.34 - $21.05 $630 - $926
-44 Reduced 0.01%
304,191 $5.04 Million
Q4 2022

Feb 10, 2023

SELL
$12.25 - $19.5 $710 - $1,131
-58 Reduced 0.02%
304,235 $5.66 Million
Q3 2022

Nov 14, 2022

SELL
$7.06 - $15.52 $1,567 - $3,445
-222 Reduced 0.07%
304,293 $3.9 Million
Q3 2021

Nov 12, 2021

SELL
$4.85 - $6.04 $1.49 Million - $1.85 Million
-306,592 Reduced 50.17%
304,515 $1.61 Million
Q2 2021

Aug 12, 2021

BUY
$4.29 - $6.05 $2,642 - $3,726
616 Added 0.1%
611,107 $3.51 Million
Q1 2021

May 14, 2021

BUY
$3.45 - $4.69 $808,279 - $1.1 Million
234,284 Added 62.28%
610,491 $2.81 Million
Q4 2020

Feb 11, 2021

BUY
$2.97 - $3.83 $1.12 Million - $1.44 Million
376,207 New
376,207 $1.26 Million

Others Institutions Holding CPRX

About CATALYST PHARMACEUTICALS, INC.


  • Ticker CPRX
  • Exchange NASDAQ
  • Sector Healthcare
  • Industry Biotechnology
  • Shares Outstandng 102,820,000
  • Market Cap $2.22B
  • Description
  • Catalyst Pharmaceuticals, Inc., a commercial-stage biopharmaceutical company, focuses on developing and commercializing therapies for people with rare debilitating, chronic neuromuscular, and neurological diseases in the United States. It offers Firdapse, an amifampridine phosphate tablets for the treatment of patients with lambert-eaton myasthe...
More about CPRX
Track This Portfolio

Track Globeflex Capital L P Portfolio

Follow Globeflex Capital L P and customize your updates to receive the information that matters most to you.

Portfolio Update

Get notified when there are updates to the investment portfolio of Globeflex Capital L P, based on Form 13F filings with the SEC.

News

Stay updated on Globeflex Capital L P with notifications on news.